Off-label use of intravitreal bevacizumab: A global conundrum.
Indian J Ophthalmol
; 72(5): 617-619, 2024 May 01.
Article
en En
| MEDLINE
| ID: mdl-38661271
ABSTRACT
Bevacizumab is a monoclonal, humanized, full-length antibody targeting vascular endothelial growth factor(VEGF-A), known for its anti-angiogenic properties. The off-label use of bevacizumab has stirred legal, financial, industrial, and ethical complexities. With its potential to treat diverse ocular conditions, this commentary delves into the multifaceted dimensions of bevacizumab's off-label utilization, encompassing clinical trials, regulatory frameworks, safety considerations, comparative effectiveness, and economic implications.
Texto completo:
1
Colección:
01-internacional
Base de datos:
MEDLINE
Asunto principal:
Inhibidores de la Angiogénesis
/
Factor A de Crecimiento Endotelial Vascular
/
Uso Fuera de lo Indicado
/
Inyecciones Intravítreas
/
Anticuerpos Monoclonales Humanizados
/
Bevacizumab
Límite:
Humans
Idioma:
En
Revista:
Indian J Ophthalmol
Año:
2024
Tipo del documento:
Article
País de afiliación:
India
Pais de publicación:
India